Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide versus artificial tears for prevention of post-phaco macular thickening in diabetic patients
IRCT20250111064355N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dorzolamide in macular edema (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Central macular thickness at 12 weeks. Started Jan 2025; status: completed.
02
Drugs
dorzolamide
03
Conditions
macular edema
Beyond the preview
Go deeper on IRCT20250111064355N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250111064355N1.